CSPHF News and Press, CStone Pharmaceuticals - Ordinary Shares From 09/26/21

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody increased median progression-free survi...

Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million deal. The company also announced a $500 million two-part deal with Providence Therapeutics of Calvery, Canada for mRNA products. Cue Health, a San Diego...

Genetron Holdings (GTH) announces that its Ayvakit (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals (CSPHF) has entered the priority review and approval process in China.Shares down 3% premarket at $18.00. During the process, the Cen...

NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. Esco Lifesciences of Singapore, an Asia-based life sciences tools company, closed an over-subscribed $200 million Series A and crossover round. Suzhou's...

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio. Discovered by CStone's part...

CStone Pharmaceuticals (CSPHF) announced that the National Medical Products Administration (“NMPA”) of China has approved Gavreto (pralsetinib) for the treatment of a certain group of adult patients with non-small cell lung cancer (“NSCLC”).The once-daily...

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion...

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. Shanghai's Zai Lab...

CStone Pharmaceuticals (CSPHF) has agreed to out-license ex-Greater China rights for sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx.Under the terms of the agreement, CStone will receive an upfront payment of $150M and up to $1.15B in milestone payments for both drugs as we...

CStone Pharmaceuticals (CSPHF) has completed the Share Subscription Agreement through which an affiliate of Pfizer (PFE) subscribed for newly issued CStone shares at ~$200M (~HK$1.55B), bringing into effect the strategic collaboration announced previously. The Hong Kong Stock Exchange has ...